(a) Day 0 Day 1 Day 2
Day 3 Day 4 Day 5
Day 6 Day 7
(b)
Supplementary Fig.4
0 1 2 3 4 5 6 7
0 20 40 60 80 100
Days Viabilities of control s-oligo mock-infected (%)
100 μm 100 μm
100 μm 100 μm 100 μm
100 μm 100 μm 100 μm
(c) Day 0 Day 1 Day 2
Day 3 Day 4 Day 5
Day 6 Day 7
(d)
Supplementary Fig.4
0 1 2 3 4 5 6 7
0 20 40 60 80 100
Days Viabilities of TLR3 knockdown mock-infected (%)
100 μm 100 μm 100 μm
100 μm 100 μm 100 μm
100 μm 100 μm
(e) Day 0 Day 1 Day 2
Day 3 Day 4 Day 5
Day 6 Day 7
(f)
Supplementary Fig.4
0 1 2 3 4 5 6 7
0 20 40 60 80 100
Days Viabilities of RIG-I knockdown mock-infected (%)
100 μm 100 μm 100 μm
100 μm 100 μm
100 μm 100 μm
100 μm
(g) Day 0 Day 1 Day 2
Day 3 Day 4 Day 5
Day 6 Day 7
(h)
Supplementary Fig.4
0 1 2 3 4 5 6 7
0 20 40 60 80 100
Days Viabilities of MDA5 knockdown mock-infected (%)
100 μm 100 μm
100 μm 100 μm 100 μm
100 μm 100 μm
100 μm